Inotuzumab ozogamicin and donor lymphocyte infusion is a safe and promising combination in relapsed acute lymphoblastic leukemia after allogeneic stem cell transplant

Hematol Oncol. 2021 Oct;39(4):580-583. doi: 10.1002/hon.2886. Epub 2021 May 7.

Authors

Cristina Papayannidis¹, Chiara Sartor², Alida Dominietto³, Elisabetta Zappone⁴, Mario Arpinati¹, Giovanni Marconi^{2

5}, Gianluca Cristiano², Jacopo Nanni², Sarah Parisi², Francesco Barbato², Stefania Paolini¹, Simona Soverini^{1

2}, Carolina Terragna¹, Valentina Robustelli², Nicoletta Testoni^{1

2}, Gabriella Chirumbolo², Antonio Curti¹, Michele Cavo^{1

2}, Francesca Bonifazi¹

Affiliations

¹ IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy.
² Dipartimento di Medicina Specialistica Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy.
³ Ematologia e Centro Trapianti, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
⁴ Haematology Unit, Policlinico Le Scotte, AOUS, Siena, Italy.
⁵ Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, FC, Italy.

PMID: 33963566
DOI: 10.1002/hon.2886

No abstract available

Keywords: acute lymphoblastic leukemia; donor lymphocyte infusion; inotuzumab Ozogamicin; stem cell transplant.

Publication types

Letter

MeSH terms

Adolescent
Adult
Antineoplastic Agents, Immunological / therapeutic use
Combined Modality Therapy
Female
Follow-Up Studies
Humans
Inotuzumab Ozogamicin / therapeutic use*
Lymphocyte Transfusion / methods*
Male
Middle Aged
Neoplasm Recurrence, Local / pathology
Neoplasm Recurrence, Local / therapy*
Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy*
Prognosis
Retrospective Studies
Salvage Therapy*
Stem Cell Transplantation / methods*
Survival Rate
Young Adult

Substances

Antineoplastic Agents, Immunological
Inotuzumab Ozogamicin